Literature DB >> 10994623

Reduced E-cadherin expression and enlargement of cancer nuclei strongly correlate with hematogenic metastasis in colorectal adenocarcinoma.

M Ikeguchi1, T Taniguchi, M Makino, N Kaibara.   

Abstract

BACKGROUND: Synchronous and metachronous hematogenic metastases are frequently detected in patients with colorectal carcinoma. Once these metastases have developed, the prognoses of patients are poor. Previously, we reported that enlargement of cancer nuclei significantly correlated with metastatic potential of gastric cancer and hepatocellular carcinoma. Moreover, recently it has been reported that reduced expression of E-cadherin is associated with tumor metastasis. To evaluate the correlation between nuclear area (NA) of cancer cells and expression of E-cadherin, and to elucidate whether these factors correlate with clinical outcome in patients with colorectal carcinoma, 105 consecutive patients were investigated.
METHODS: In each case, the NAs of 600 cancer nuclei were analyzed by means of a computer-assisted image analysis system and E-cadherin expression was detected immunohistochemically by an anti-E-cadherin monoclonal antibody. The expression levels of E-cadherin were divided into three groups according to the percentages of E-cadherin-positive cells (level 0: positive cells < or = 50%, level 1: 50% < positive cells < or = 80%, level 2: positive cells > 80%).
RESULTS: The mean NA of cancer cells in 105 tumors was 57 microm2. The NAs of cancer cells enlarged in proportion to the decrease of E-cadherin expression levels (level 0, n = 48, 62 microm2; level 1, n = 35, 57 microm2, level 2, n = 22, 46 microm2, P = 0.002). The 10-year survival rates decreased in proportion to the reduced E-cadherin expression levels (80% in level 2, 64% in level 1, and 42% in level 0, P = 0.004). Moreover, the 10-year survival rate of 54 patients with large NA tumors (< or = 54 microm2, 36%) was significantly poorer than that of 51 patients with small NA tumors (< 54 microm2, 80%, P < 0.001). The NA of cancer cells was recognized as an important predictor for prognosis and hematogenic metastasis. Although reduced E-cadherin expression was not recognized as the risk factor for hematogenic metastasis, 80% of patients who developed hematogenic metastasis had tumors with both enlarged cancer nuclei and reduced E-cadherin expression.
CONCLUSIONS: Detection of NA of cancer cells and E-cadherin expression in patients with colorectal carcinoma may reveal important information for hematogenic metastasis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10994623     DOI: 10.1080/003655200750023219

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  21 in total

1.  Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues.

Authors:  Matthias Steinert; Manja Wobus; Carsten Boltze; Alexander Schütz; Mandy Wahlbuhl; Jörg Hamann; Gabriela Aust
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

Review 2.  Cadherins down-regulation: towards a better understanding of their relevance in colorectal cancer.

Authors:  Lorena Losi; Tommaso Zanocco-Marani; Alexis Grande
Journal:  Histol Histopathol       Date:  2020-06-22       Impact factor: 2.303

3.  Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability.

Authors:  Maria S Pino; Hirotoshi Kikuchi; Min Zeng; Maria-Teresa Herraiz; Isabella Sperduti; David Berger; Do-Youn Park; A John Iafrate; Lawrence R Zukerberg; Daniel C Chung
Journal:  Gastroenterology       Date:  2009-12-21       Impact factor: 22.682

4.  An increase in the number of adhesion proteins with altered expression is associated with an increased risk of cancer death for colon carcinoma patients.

Authors:  Johan Bondi; Geir Bukholm; Jahn M Nesland; Arne Bakka; Ida R K Bukholm
Journal:  Int J Colorectal Dis       Date:  2005-06-04       Impact factor: 2.571

5.  E-cadherin expression pattern in primary colorectal carcinomas and their metastases reflects disease outcome.

Authors:  Adam Elzagheid; Annika Algars; Riyad Bendardaf; Hanan Lamlum; Raija Ristamaki; Yrjo Collan; Kari Syrjanen; Seppo Pyrhonen
Journal:  World J Gastroenterol       Date:  2006-07-21       Impact factor: 5.742

6.  New specific molecular targets for radio-chemotherapy of rectal cancer.

Authors:  Kristin Snipstad; Christopher G Fenton; Jørn Kjaeve; Guanglin Cui; Endre Anderssen; Ruth H Paulssen
Journal:  Mol Oncol       Date:  2009-11-25       Impact factor: 6.603

7.  The Prognostic Impact of Protein Expression of E-Cadherin-Catenin Complexes Differs between Rectal and Colon Carcinoma.

Authors:  Rolf Aamodt; Johan Bondi; Solveig Norheim Andersen; Arne Bakka; Geir Bukholm; Ida R K Bukholm
Journal:  Gastroenterol Res Pract       Date:  2010-08-16       Impact factor: 2.260

Review 8.  Regulation of metastasis in colorectal adenocarcinoma: a collision between development and tumor biology.

Authors:  J Joshua Smith; Natasha G Deane; Punita Dhawan; R Daniel Beauchamp
Journal:  Surgery       Date:  2008-07-25       Impact factor: 3.982

Review 9.  Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature.

Authors:  Lun-Xiu Qin; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-17       Impact factor: 4.553

10.  Contribution of in vitro comparison of colorectal carcinoma cells from primary and metastatic lesions to elucidation of mechanisms of tumor progression and response to anticancer therapy.

Authors:  Lukáš Krbal; Veronika Hanušová; Jiří Soukup; Stanislav John; Petra Matoušková; Aleš Ryška
Journal:  Tumour Biol       Date:  2016-01-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.